Skip to main content
Clinical Trials/NCT03570762
NCT03570762
Completed
Not Applicable

Long Term Outcomes Of Hybrid Percutaneous Intervention With Bioresorbable Vascular Scaffolds And Drug Eluting Stents For Complex Coronary Artery Lesions

Liv Hospital Ankara0 sites40 target enrollmentFebruary 1, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Liv Hospital Ankara
Enrollment
40
Primary Endpoint
target lesion failure
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Bioresorbable vascular scaffolds (BVS) are considered as a new revolution in coronary intervention due to their potential advantages for long term follow up. However, current generation BVS have also some drawbacks that restrict the use for complex lesions. Using BVS and drug eluting stents (DES) together -implanting DES for BVS inappropriate segments -may be a feasible option to avoid the disadvantages of permanent foreign body and to reduce very late adverse events. In this context, we investigated the clinical outcomes following treatment with hybrid strategy with concomitant use of BVS and DES for complex lesions. A single center retrospective cohort was performed enrolling 40 patients with complex lesions treated with hybrid approach from February 2015 up to April 2017. Lesion segments with a large plaque burden and/or severe calcification, aorto-ostial and bifurcation lesions that may be unfavorable for BVS, treated with DES. BVS and DES were implanted with minimal overlap of DES and BVS struts. The primary end-point was target lesion failure (TLF) which was a composite of cardiac death, target vessel myocardial infarction and target lesion revascularization (TLR). During follow-up, coronary angiography was performed when patients had ischemic symptoms.

Registry
clinicaltrials.gov
Start Date
February 1, 2015
End Date
April 30, 2017
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Liv Hospital Ankara
Responsible Party
Principal Investigator
Principal Investigator

Erol Kalender

Principal investigator

Liv Hospital Ankara

Eligibility Criteria

Inclusion Criteria

  • treated with BVS in combination with DES

Exclusion Criteria

  • treated with only DES or BVS

Outcomes

Primary Outcomes

target lesion failure

Time Frame: 2 year

a composite of cardiac death, target vessel myocardial infarction and target lesion revascularization

Similar Trials